BIO-TECHNE Corp (TECH) Gross Margin
- Gross margin · 12 months: Value 65.77%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 65.77% | Gross profit / revenue. Period ending 2026-06-30. $799.07M ÷ $1.22B × 100 ≈ 65.77% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 799.07M USD | Gross Profit |
| Revenue | 1.22B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 415.97M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $799.07M | $1.22B | $415.97M | 65.77% |
| 2026-03-31 | $786.49M | $1.21B | $424.32M | 64.96% |
| 2025-12-31 | $792.76M | $1.22B | $422.82M | 65.22% |
| 2025-09-30 | $795.37M | $1.22B | $421.37M | 65.37% |
| 2025-06-30 | $790.27M | $1.22B | $429.36M | 64.80% |
| 2025-03-31 | $794.81M | $1.21B | $413.96M | 65.75% |
| 2024-12-31 | $784.85M | $1.20B | $411.17M | 65.62% |
| 2024-09-30 | $767.55M | $1.17B | $404.03M | 65.51% |
| 2024-06-30 | $769.73M | $1.16B | $389.33M | 66.41% |
| 2024-03-31 | $771.08M | $1.15B | $383.21M | 66.80% |
| 2023-12-31 | $768.64M | $1.14B | $376.36M | 67.13% |
| 2023-09-30 | $775.41M | $1.14B | $368.57M | 67.78% |
| 2023-06-30 | $769.82M | $1.14B | $366.89M | 67.72% |
| 2023-03-31 | $765.47M | $1.12B | $358.14M | 68.13% |
| 2022-12-31 | $764.76M | $1.12B | $355.08M | 68.29% |
| 2022-09-30 | $765.09M | $1.12B | $352.44M | 68.46% |
| 2022-06-30 | $756.50M | $1.11B | $349.10M | 68.42% |
| 2022-03-31 | $732.09M | $1.08B | $344.31M | 68.01% |
| 2021-12-31 | $698.91M | $1.03B | $330.67M | 67.88% |
| 2021-09-30 | $666.12M | $984.55M | $318.44M | 67.66% |
| 2021-06-30 | $632.85M | $931.03M | $298.18M | 67.97% |
| 2021-03-31 | $570.22M | $847.84M | $277.62M | 67.26% |
| 2020-12-31 | $532.01M | $798.97M | $266.96M | 66.59% |
| 2020-09-30 | $502.51M | $759.65M | $257.14M | 66.15% |
| 2020-06-30 | $483.19M | $738.69M | $255.50M | 65.41% |
| 2020-03-31 | $498.14M | $754.52M | $256.38M | 66.02% |
| 2019-12-31 | $492.69M | $744.70M | $252.02M | 66.16% |
| 2019-09-30 | $484.30M | $734.28M | $249.98M | 65.96% |
| 2019-06-30 | $473.49M | $714.01M | $240.51M | 66.31% |
| 2019-03-31 | $467.41M | (m) | $235.18M | (m) |
| 2018-12-31 | $453.06M | (m) | $228.65M | (m) |
| 2018-09-30 | $441.88M | (m) | $219.47M | (m) |
| 2018-06-30 | $432.14M | (m) | $210.85M | (m) |
| 2018-03-31 | $412.33M | (m) | $206.98M | (m) |
| 2017-12-31 | $398.76M | $599.38M | $200.63M | 66.53% |
| 2017-09-30 | $385.06M | $577.03M | $191.97M | 66.73% |
| 2017-06-30 | $374.54M | $563.00M | $188.46M | 66.53% |
| 2017-03-31 | $353.43M | $541.19M | $187.76M | 65.31% |
| 2016-12-31 | $349.23M | $528.12M | $178.89M | 66.13% |
| 2016-09-30 | $345.74M | $517.22M | $171.49M | 66.85% |
| 2016-06-30 | $336.66M | $499.02M | $162.36M | 67.46% |
| 2016-03-31 | $326.06M | $481.92M | $155.87M | 67.66% |
| 2015-12-31 | $315.45M | $465.11M | $149.66M | 67.82% |
| 2015-09-30 | $309.60M | $456.15M | $146.55M | 67.87% |
| 2015-06-30 | $307.28M | $452.25M | $144.97M | 67.94% |
| 2015-03-31 | $291.78M | $427.11M | $135.32M | 68.32% |
| 2014-12-31 | $280.51M | $408.50M | $127.99M | 68.67% |
| 2014-09-30 | $263.36M | $380.57M | $117.21M | 69.20% |
| 2014-06-30 | $251.41M | $357.76M | $106.35M | 70.27% |
| 2014-03-31 | $246.94M | $344.71M | $97.78M | 71.63% |
| 2013-12-31 | $239.97M | $330.15M | $90.18M | 72.69% |
| 2013-09-30 | $236.64M | $321.22M | $84.58M | 73.67% |
| 2013-06-30 | $231.11M | $310.57M | $79.47M | 74.41% |
| 2013-03-31 | $230.86M | $309.78M | $78.92M | 74.52% |
| 2012-12-31 | $233.09M | $312.41M | $79.32M | 74.61% |
| 2012-09-30 | $233.00M | $311.99M | $78.99M | 74.68% |
| 2012-06-30 | $235.80M | $314.56M | $78.76M | 74.96% |
| 2012-03-31 | $236.57M | $313.92M | $77.35M | 75.36% |
| 2011-12-31 | $233.52M | $306.57M | $73.05M | 76.17% |
| 2011-09-30 | $230.73M | $299.61M | $68.88M | 77.01% |
| 2011-06-30 | $224.94M | $289.96M | $65.03M | 77.57% |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | $214.15M | $269.05M | $54.90M | 79.60% |
| 2010-03-31 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) |
| 2009-06-30 | $208.03M | $263.96M | $55.92M | 78.81% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |